Document is current
Any future updates will be listed below
-
Authors
Rasmussen, Nicklas Højgaard-hessellund
Dal, Jakob
Jensen, Morten Hasselstrøm
Kvist, Annika Vestergaard
van den Bergh, Joop
Hirata, Rogerio Pessoto
Vestergaard, Peter
- License Information
-
More Information
Article History
Received: 13 March 2022
Accepted: 9 November 2022
First Online: 9 December 2022
Declarations
:
: The methods used have been tested and performed in several studies both in Denmark and abroad, and no long-term side effects have been reported. The risks associated with the project are few, and the tests implied limited risks. The potential benefits in terms of well-being were large and estimated to outweigh the potential risks. The trial was reported to the local ethical committee in the North Jutland Region (N-2019–0004). The trial was conducted in compliance with Harmonized Tripartite Guideline for Good Clinical Practice (ICH GCP) and applicable regulatory requirements and in accordance with the Helsinki Declaration for biomedical research involving test participants [CitationRef removed, CitationRef removed]. Finally, the project was reported to the North Jutland Research department (ID-number of 2018–174).
: Consent for each participant was achieved.
: Consent for each participant was achieved.
: Peter Vestergaard is head of research in the Steno Diabetes Center North Denmark sponsored by the Novo Nordisk Foundation. Joop van den Bergh is involved in research that is sponsored by Amgen, Eli Lilly, and UCB. Morten Hasselstrøm Jensen is a former employee of Novo Nordisk and holds shares in Novo Nordisk. Nicklas H. Rasmussen holds shares in Novo Nordisk. Jakob Dal: unrestricted research grants and lecture fee from Pfizer and IPSEN. The other authors Rogerio Pessoto Hirata and Annika Kvist declare that they have no conflict of interest.
